Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 7 art units • 11 examiners • 0 of 12 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
BEIGENE, LTD. has 12 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 11 examiners across 7 art units, indicating a distributed portfolio with repeated examiner and art-unit assignments. TOWNSLEY, SARA ELIZABETH is the busiest examiner, with 2 pending matters.
The two matters before TOWNSLEY, SARA ELIZABETH provide a defined opportunity to coordinate examiner-specific review. The remaining matters span other assignments, so counsel should combine centralized portfolio oversight with tailored analysis of each examiner’s record and each art unit’s technical context.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (8%) |
| §102 only | 1 (8%) |
| §112 only | 2 (17%) |
| Double-patenting only | 1 (8%) |
| Double-patenting + other | 2 (17%) |
| Multi-statute (no §101) | 5 (42%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TOWNSLEY, SARA ELIZABETH | 2 | 25.6% | +48.2% |
| ARCORIA, PAUL JOSEPH | 1 | 100.0% | +0.0% |
| CHICKS, ASHLI ARIANA | 1 | 60.0% | +51.0% |
| CHEN, PO-CHIH | 1 | 74.3% | +14.7% |
| SHUPE, ELIZABETH A | 1 | 65.8% | +45.5% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.0% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.4% |
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
| SEITZ, ANTHONY JOSEPH | 1 | 67.8% | +27.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18938467 | METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR | ARCORIA, PAUL JOSEPH | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263448 | METHODS OF TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS | SEITZ, ANTHONY JOSEPH | 29d |
| 18897194 | KAT6 Inhibitors | CHICKS, ASHLI ARIANA | — |
| 18748855 | SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | — |
| 18678898 | Compounds for the Degradation of EGFR Kinase | TOWNSLEY, SARA ELIZABETH | — |
| 18620353 | ANTI-CLDN6 ANTIBODIES AND METHODS OF USE | CHERNYSHEV, OLGA N | — |
| 18513223 | ANTI-CEA AND ANTI-CD137 MULTISPECIFIC ANTIBODIES AND METHODS OF USE | DUNN, LINDSAY MICHELLE | — |
| 18253720 | METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING BTK INHIBITORS | SHOWALTER, ALEXANDER KEITH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263448 | METHODS OF TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS | SEITZ, ANTHONY JOSEPH | 29d |
| 18897194 | KAT6 Inhibitors | CHICKS, ASHLI ARIANA | — |
| 18748855 | SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | — |
| 18680922 | Methods of Synthesis of Chiral 3,5-Disubstituted Morpholine Compounds and Intermediates Useful Therein | CHEN, PO-CHIH | — |
| 18678898 | Compounds for the Degradation of EGFR Kinase | TOWNSLEY, SARA ELIZABETH | — |
| 18697500 | ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF | SHUPE, ELIZABETH A | — |
| 18620353 | ANTI-CLDN6 ANTIBODIES AND METHODS OF USE | CHERNYSHEV, OLGA N | — |
| 18603755 | Pyrazolopyridinone Compounds | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 1629 | 4 |
| 1621 | 2 |
| 1626 | 1 |
| 1643 | 1 |
| 1625 | 1 |
| 1647 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18938467 | METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR | ARCORIA, PAUL JOSEPH | 1621 | §103 | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18897194 | KAT6 Inhibitors | CHICKS, ASHLI ARIANA | 1626 | §102§103§112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18748855 | SOLID FORMS OF A TYK2 INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | TOWNSLEY, SARA ELIZABETH | 1629 | §112 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18680922 | Methods of Synthesis of Chiral 3,5-Disubstituted Morpholine Compounds and Intermediates Useful Therein | CHEN, PO-CHIH | 1621 | §102 | Non-Final OA | — | Pending | May 31, 2024 |
| 18678898 | Compounds for the Degradation of EGFR Kinase | TOWNSLEY, SARA ELIZABETH | 1629 | DP | Non-Final OA | — | Pending | May 30, 2024 |
| 18697500 | ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF | SHUPE, ELIZABETH A | 1643 | §103§112DP | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18620353 | ANTI-CLDN6 ANTIBODIES AND METHODS OF USE | CHERNYSHEV, OLGA N | — | §102§112 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18603755 | Pyrazolopyridinone Compounds | CHANDRAKUMAR, NIZAL S | 1625 | §112Other | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18513255 | ANTI-CEA ANTIBODIES AND METHODS OF USE | ALLEN, MARIANNE P | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18513223 | ANTI-CEA AND ANTI-CD137 MULTISPECIFIC ANTIBODIES AND METHODS OF USE | DUNN, LINDSAY MICHELLE | 1644 | §103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18263448 | METHODS OF TREATING CHRONIC ACTIVE ANTIBODY-MEDIATED REJECTION USING BTK INHIBITORS | SEITZ, ANTHONY JOSEPH | 1629 | §102§103 | Final Rejection | 29d | Pending | Jul 28, 2023 |
| 18253720 | METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS USING BTK INHIBITORS | SHOWALTER, ALEXANDER KEITH | 1629 | §103§112 | Final Rejection | — | Pending | May 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBEIGENE, LTD. has 12 pending office actions as of October 2026, spread across 7 art units and 11 examiners.
Sara Elizabeth Townsley has the most, with 2 of BEIGENE, LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
